Navigation Links
New Study by BioTrends Highlights Anemia Practice Patterns According to Anemia Managers in Both Dialysis Units and CKD Clinics/Offices
Date:9/11/2008

EXTON, Pa., Sept. 11 /PRNewswire/ -- BioTrends Research Group, Inc. is pleased to announce the release of TreatmentTrends(TM): Anemia Managers. This is the first report in a series conducted with Anemia Managers. It is based on the results of an on-line survey completed by 150 Anemia Managers -- 100 working with dialysis patients and 50 working with later stage Chronic Kidney Disease (CKD) patients, and qualitative interviews with a subset of 25 respondents. The report focuses on the management of renal anemia, including the use of ESAs and IV iron. Comparisons to Nephrologist responses regarding anemia management are made throughout the report, based on data from the recently published BioTrends TreatmentTrends(TM): Nephrology report.

In the dialysis market, Anemia Managers are very involved in monitoring lab values related to ESA and IV iron use and making therapy decisions based on labs and protocols. Similar to Nephrologists, the vast majority of Anemia Managers report that ESA safety issues have impacted their use of ESAs in dialysis. Both Anemia Managers and Nephrologists most often report protocol changes and ESA dose reductions at lower hemoglobin levels as types of changes, but Anemia Managers were more likely to report that they are using lower average doses of ESAs, monitoring hemoglobins more frequently, and placing more emphasis on a patient's IV iron status. Relatedly, Anemia Managers predict a significant increase in their use of IV iron in the next three months, and over one-third report changing their IV iron protocol in the past three months -- most often allowing higher levels of ferritin before holding IV iron and making more effort to keep patients on maintenance therapy (by extending dosing frequency, for example) instead of discontinuing therapy. American Regent's Venofer is the market share leader in the hemodialysis market over Watson's Ferrlecit.

In the CKD market, similar to the dialysis market, Anemia Managers are often in charge of monitoring lab values and adjusting treatment based on protocols for both ESAs and IV iron. In CKD, however, Anemia Managers tend only to see the patients who Nephrologists deem are in need of anemia management. The nephrology office or CKD clinic is the most common place patients receive their ESA therapy. For patients who do not receive their ESA at the office, administration location is typically driven by geography or insurance. From a brand perspective, Amgen's Aranesp and Ortho-Biotech's Procrit continue to battle for market leadership in CKD. Anemia Managers tend to feel that Procrit has an advantage on tolerability, ease of dosing modifications, and reimbursement, whereas Aranesp has an advantage for patients who self-inject. IV iron is used with much less frequency in CKD patients compared to ESAs; however, Anemia Managers predict a significant increase in their use of IV iron in the next three months. Potential reasons include an increased focus by managed care on iron status to approve ESAs and restrictions on starting ESAs (often Hb less than or equal to 10g/dL). For CKD patients who do receive IV iron, most do so on a repletion basis, commonly 1000mg over five infusions. The most desired feature in a new IV iron product among Anemia Managers working with CKD patients is the ability to give larger doses at once to reduce the number of patient visits, a feature that AMAG Pharmaceuticals may be able to capitalize on with Ferumoxytol, an IV iron product currently under review by the FDA.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit http://www.bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 2016 , ... UAS LifeSciences, one of the leading manufacturers ... Probiotics, into Target stores nationwide. The company, which has been manufacturing high quality ... list of well-respected retailers. This list includes such fine stores as Whole Foods, ...
(Date:6/23/2016)... June 23, 2016 Houston Methodist Willowbrook ... Cy-Fair Sports Association to serve as their official ... Houston Methodist Willowbrook will provide sponsorship support, athletic ... with association coaches, volunteers, athletes and families. ... Cy-Fair Sports Association and to bring Houston Methodist ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... , June 23, 2016 Apellis Pharmaceuticals, ... 1 clinical trials of its complement C3 inhibitor, ... and multiple ascending dose studies designed to assess ... of subcutaneous injection in healthy adult volunteers. ... either as a single dose (ranging from 45 ...
Breaking Biology Technology:
(Date:6/3/2016)... 2016 Das DOTM ... Nepal hat ein 44 Millionen ... Kennzeichen, einschließlich Personalisierung, Registrierung und IT-Infrastruktur, an ... und Implementierung von Identitätsmanagementlösungen. Zahlreiche renommierte internationale ... teilgenommen, aber Decatur wurde als konformste und ...
(Date:6/2/2016)... YORK , June 2, 2016   The Weather ... is announcing Watson Ads, an industry-first capability in which consumers ... by being able to ask questions via voice or text ... Marketers have long sought ... the consumer, that can be personal, relevant and valuable; and ...
(Date:6/1/2016)... 1, 2016 Favorable Government Initiatives ... and Criminal Identification to Boost Global Biometrics System Market ... TechSci Research report, " Global Biometrics Market By ... and Opportunities, 2011 - 2021", the global biometrics market ... on account of growing security concerns across various end ...
Breaking Biology News(10 mins):